Welcome to our dedicated page for Sanara MedTech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara MedTech stock.
Sanara MedTech Inc. (SMTI) is a leading medical technology company that aims to revolutionize the wound care and skincare markets through innovative solutions. Founded in 1982 and headquartered in Fort Worth, Texas, Sanara MedTech focuses on developing and commercializing technologies that improve clinical outcomes for patients while simultaneously reducing healthcare costs.
The company operates through its subsidiary, Wound Care Innovations, LLC, and offers a range of collagen-based wound care products under the brand name CellerateRX. These products are marketed for treating various types of wounds, including pressure ulcers, diabetic ulcers, surgical wounds, and burns. Available in both gel and powder forms, CellerateRX is designed to serve healthcare providers such as physicians, clinics, and hospitals.
Sanara MedTech's portfolio extends beyond surgical wound care, encompassing a comprehensive suite of chronic wound care products. The company's notable offerings include HYCOL Hydrolyzed Collagen, BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel. These products enable Sanara MedTech to deliver extensive wound and skincare solutions across all care settings, from acute to post-acute environments.
With a strategic focus on transformative technologies, Sanara MedTech holds worldwide licenses for certain proprietary technologies and processes. This positions the company at the forefront of advancing wound care treatment protocols. Recent achievements highlight the company's commitment to innovation and quality, making it a key player in the medical technology landscape.
Sanara MedTech also prioritizes transparent communication with its investors and stakeholders. For the latest updates and developments, the company's investor relations team is readily accessible, ensuring stakeholders are well-informed about performance metrics, ongoing projects, and future prospects.
Overall, Sanara MedTech Inc. continues to set the standard in wound care and skincare solutions, contributing significantly to the healthcare sector by enhancing patient care and operational efficacy.
InfuSystem Holdings (INFU) and Sanara MedTech (SMTI) have formed a partnership called SI Wound Care to enhance wound care solutions. This collaboration aims to improve patient outcomes, reduce healthcare costs, and increase satisfaction for both patients and providers. InfuSystem plans to leverage its extensive distribution network as a participating in-network provider for over 95% of the U.S. population. The partnership will include Cork Medical’s negative pressure wound therapy devices and Sanara’s advanced product line, targeting both chronic and acute wounds.
Sanara MedTech Inc (NASDAQ: SMTI), located in Fort Worth, Texas, announced the release of its quarterly earnings results for the period ending September 30, 2022. The earnings will be disclosed on November 14, 2022, followed by a conference call on November 15, 2022, at 9:00 a.m. Eastern Time. Investors can access the call via phone or through a live webcast. Sanara focuses on advanced wound care and surgical tissue repair, aiming to enhance patient outcomes.
Sanara MedTech Inc (NASDAQ: SMTI) will present at the 7th annual MicroCap Leadership Summit on September 16, 2022. CEO Zach Fleming will represent the company at this virtual event attended by over 150 investors globally. Sanara was chosen as one of twelve presenting companies, highlighting its focus on improving patient outcomes through advanced wound and skincare solutions. The company offers a range of products utilized in surgical and chronic wound care, and continues to pursue innovations in healthcare technologies.
Sanara MedTech Inc. (NASDAQ: SMTI) reported strong financial results for the second quarter of 2022, achieving net revenues of $9.7 million, a 54% increase from the same quarter last year. The company generated over $3 million in sales each month, a first for them. Strategic highlights included an increase in facilities selling their product CellerateRX to 1,580. However, the company also recorded a net loss of $3.3 million, up from a $1.2 million loss a year earlier, primarily due to higher SG&A and R&D expenses.
Sanara MedTech Inc (NASDAQ: SMTI) announced the release of its second-quarter earnings for the period ending June 30, 2022. The earnings report will be issued on August 15, 2022, post-market close, followed by a conference call on August 16 at 9:00 a.m. ET. The call will be accessible via phone and live webcast. Sanara specializes in wound care and surgical products, focusing on improving patient outcomes through innovation and strategic partnerships. The company is dedicated to expanding its product pipeline, emphasizing advanced healing solutions.
Sanara MedTech announced the successful acquisition of Scendia Biologics, closed on July 1, 2022, for $7.4 million, comprising $1.4 million cash and $6.0 million in stock. Scendia, previously a sub-distributor and partner, had 2021 revenues of $8.3 million. The acquisition aims to enhance Sanara's product offerings, expand partnerships with health systems, and is expected to positively impact earnings per share in Q3 2022.
Sanara MedTech reported its financial results for Q1 2022, achieving a record revenue of $7.8 million, up 56% YoY. The company noted significant operational achievements, including generating over $3 million in sales within a single month and expanding its distribution network to approximately 1,250 facilities. The first quarter also marked the completion of the acquisition of Precision Healing. However, Sanara recorded a net loss of $3.2 million, attributed primarily to increased selling, general, and administrative expenses.
Sanara MedTech Inc (NASDAQ: SMTI) announced its first-quarter earnings release date for the period ending March 31, 2022. The earnings report will be published after market close on May 16, 2022, followed by a conference call on May 17, 2022, at 9:00 a.m. ET. Interested parties can join the call using the toll-free number provided. The Company focuses on improving patient outcomes with advanced wound care and surgical products. Its offerings include various innovative solutions for healthcare settings.
Sanara MedTech Inc. has completed its merger with Precision Healing Inc., enhancing its product portfolio in surgical and chronic wound care. This strategic acquisition aims to improve patient outcomes and expand Sanara's presence in the North American advanced wound care and surgical tissue repair markets. With a focus on evidence-based healing solutions, Sanara markets products like CellerateRX® and the BIAKŌS™ line, and seeks to drive innovation in telehealth and wound care.
Sanara MedTech Inc has announced a definitive agreement to merge with Precision Healing Inc. The boards of both companies approved the merger, expected to close today. Sanara has been a stakeholder in Precision Healing since 2020, holding 25.7% equity. The transaction comprises approximately $5.1 million in stock and cash, valuing Precision Healing at about $7.8 million. The merger aims to enhance diagnostic technology for chronic wounds, improving patient outcomes and offering innovative treatment protocols through advanced algorithms and multispectral imaging.
FAQ
What is the current stock price of Sanara MedTech (SMTI)?
What is the market cap of Sanara MedTech (SMTI)?
What is Sanara MedTech Inc. known for?
What products does Sanara MedTech offer?
Who are the primary customers for Sanara MedTech's products?
Where is Sanara MedTech Inc. headquartered?
When was Sanara MedTech Inc. founded?
How does Sanara MedTech contribute to healthcare cost reduction?
What forms does CellerateRX come in?
What conditions can CellerateRX treat?
How does Sanara MedTech ensure transparent communication with investors?
Who is the current Director of Investor Relations at Sanara MedTech?
